Scarica l'app Stockscreener
35.24
0.54%
0.21
Precedente Chiudi:
$35.03
Aprire:
$34.93
Volume 24 ore:
269.57K
Relative Volume:
0.81
Capitalizzazione di mercato:
$1.78B
Reddito:
$357.71M
Utile/perdita netta:
$-20.10M
Rapporto P/E:
-85.20
EPS:
-0.4136
Flusso di cassa netto:
$28.67M
1 W Prestazione:
+5.61%
1M Prestazione:
-2.68%
6M Prestazione:
-2.30%
1 anno Prestazione:
+7.71%
Intervallo 1D:
$34.54
$35.55
Intervallo di 1 settimana:
$33.00
$35.95
Portata 52W:
$23.15
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Confronta IMCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
35.20 | 1.77B | 357.71M | -20.10M | 28.67M | -0.4136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | UBS | Sell → Buy |
| 2025-10-31 | Iniziato | Wells Fargo | Overweight |
| 2025-09-18 | Ripresa | Guggenheim | Neutral |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2025-05-27 | Iniziato | Deutsche Bank | Buy |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-10-24 | Iniziato | UBS | Sell |
| 2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Iniziato | Needham | Buy |
| 2023-08-16 | Iniziato | CapitalOne | Overweight |
| 2023-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-30 | Iniziato | Guggenheim | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-30 | Iniziato | Barclays | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-08-08 | Iniziato | Cowen | Outperform |
| 2022-08-02 | Iniziato | BTIG Research | Buy |
| 2022-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-20 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | Goldman | Neutral |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
| 2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data - sharewise.com
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? - Nasdaq
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate - Finviz
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Yahoo Finance
Immunocore (NASDAQ:IMCR) Upgraded at Zacks Research - Defense World
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Immunocore outlines 2026 strategy at J.P. Morgan conference - Investing.com
Immunocore outlines 2026 strategy at J.P. Morgan conference By Investing.com - Investing.com South Africa
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Immunocore (NASDAQ:IMCR) Shares Gap UpWhat's Next? - MarketBeat
UBS assumes coverage on Immunocore stock with Buy rating, $55 target By Investing.com - Investing.com South Africa
UBS assumes coverage on Immunocore stock with Buy rating, $55 target - Investing.com India
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Hudson Bay Capital Management LP Sells 49,382 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Bellevue Group AG Increases Stake in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eschler Asset Management LLP Invests $1.26 Million in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
1,024,288 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Purchased by BVF Inc. IL - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Position Lowered by Armistice Capital LLC - MarketBeat
Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance - Finviz
Immunocore (NASDAQ:IMCR) Sets New 52-Week High – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 1-Year HighHere's What Happened - MarketBeat
Schroder Investment Management Group Boosts Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore stock hits 52-week high at 40.71 USD By Investing.com - Investing.com India
Immunocore stock hits 52-week high at 40.71 USD - Investing.com
Immunocore (NASDAQ:IMCR) Shares Gap DownHere's What Happened - MarketBeat
Immunocore Holdings stock hits 52-week high at $40.53 - Investing.com
Immunocore Holdings stock hits 52-week high at $40.53 By Investing.com - Investing.com South Africa
Immunocore announces board and executive departures with no reported disagreements - Investing.com
Immunocore (NASDAQ:IMCR) Sets New 1-Year HighStill a Buy? - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 52-Week HighWhat's Next? - MarketBeat
Immunocore stock hits 52-week high at 39.5 USD - Investing.com
Immunocore at Jefferies Conference: Strategic Expansion and Innovation By Investing.com - Investing.com South Africa
Immunocore at Jefferies Conference: Strategic Expansion and Innovation - Investing.com
A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy - Sahm
Acadian Asset Management LLC Acquires 72,355 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Fiera Capital Corp Purchases 7,924 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Positive Hepatitis B Trial Data Might Change the Case for Investing in Immunocore Holdings (IMCR) - Sahm
Immunocore reports promising data for HBV treatment candidate By Investing.com - Investing.com South Africa
Immunocore reports promising data for HBV treatment candidate - Investing.com
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting - GlobeNewswire Inc.
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $60.89 - Defense World
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? - sharewise.com
State of New Jersey Common Pension Fund D Purchases New Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunocore Holdings Plc Adr Azioni (IMCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Option Exercise |
17.46 |
572 |
9,987 |
572 |
| Berman David M | HEAD OF R&D |
Dec 04 '25 |
Sale |
40.26 |
31,341 |
1,261,789 |
0 |
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Sale |
40.14 |
572 |
22,960 |
0 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Option Exercise |
17.46 |
69,404 |
1,211,794 |
69,404 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Option Exercise |
17.46 |
5,521 |
96,397 |
5,521 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Sale |
40.12 |
69,404 |
2,784,488 |
0 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Sale |
40.09 |
5,521 |
221,337 |
0 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Option Exercise |
17.46 |
18,020 |
314,629 |
18,020 |
| Berman David M | HEAD OF R&D |
Nov 24 '25 |
Option Exercise |
17.46 |
100 |
1,746 |
100 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Sale |
40.03 |
18,020 |
721,341 |
0 |
3.31%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):